RTTNews | Sep 9, 2020 09:59AM EDT

09:58 Wednesday, September 9, 2020 (RTTNews.com) - iBio, Inc. (IBIO) said the company has selected IBIO-201, its LicKM-ubunit vaccine, as leading candidate for the prevention of SARS-CoV-2 infection. The company plans to engage additional collaborators for further characterization and testing of IBIO-201 prior to performing GLP toxicology studies.

"Our decision to evaluate IBIO-200 and IBIO-201 in tandem, and in combination with multiple adjuvants, proved beneficial given the results observed with IBIO-201 in preclinical studies. While IBIO-201 produced significantly higher anti-spike neutralizing antibody titers than IBIO-200, we are still encouraged by the potential of IBIO-200," said Tom Isett, CEO of iBio.

Read the original article on RTTNews ( https://www.rttnews.com/3127289/ibio-selects-ibio-201-as-leading-vaccine-candidate-for-prevention-of-sars-cov-2.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved